We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+29.89%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.5B
AUM Growth
+$361M
Cap. Flow
+$95.2M
Cap. Flow %
6.35%
Top 10 Hldgs %
63.32%
Holding
74
New
17
Increased
21
Reduced
30
Closed
4

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$33M
2
RVTY icon
Revvity
RVTY
+$31.9M
3
PFE icon
Pfizer
PFE
+$30.6M
4
VTRS icon
Viatris
VTRS
+$15.9M
5
INSP icon
Inspire Medical Systems
INSP
+$13.6M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$35.6M
2
IMGN
Immunogen Inc
IMGN
+$22.2M
3
ARGX icon
argenx
ARGX
+$12.1M
4
ILMN icon
Illumina
ILMN
+$12.1M
5
KRYS icon
Krystal Biotech
KRYS
+$8.65M

Sector Composition

Rank Sector Weight
1 Healthcare 89.26%
2 Miscellaneous 10.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STOK icon
51
Stoke Therapeutics
STOK
$2.04B
$3.92M 0.26%
+290,000
New +$1.76M
CRBP icon
52
Corbus Pharmaceuticals
CRBP
$211M
$3.49M 0.23%
+88,934
New +$2.19M
KRYS icon
53
Krystal Biotech
KRYS
$10.4B
$3.3M 0.22%
18,557
-62,241
-77% -$8.65M
ALEC icon
54
Alector
ALEC
$261M
$3.23M 0.22%
+536,171
New +$3.51M
AVTR icon
55
Avantor
AVTR
$9.86B
$3.21M 0.21%
125,394
-570
-0.5% -$13.6K
IQV icon
56
IQVIA
IQV
$43.1B
$3.08M 0.21%
12,178
-85
-0.7% -$19.8K
MOR
57
DELISTED
MorphoSys AG American Depositary Shares
MOR
$3.01M 0.2%
+165,924
New +$2.45M
VRDN icon
58
Viridian Therapeutics
VRDN
$2.61B
$2.49M 0.17%
142,075
+4,732
+3% +$91.7K
MOH icon
59
Molina Healthcare
MOH
$10.4B
$2.39M 0.16%
5,828
-289
-5% -$112K
XOMA
60
DELISTED
Xoma
XOMA
$2.33M 0.16%
97,065
+3,338
+4% +$74.8K
IFRX icon
61
InflaRx
IFRX
$329M
$2.01M 0.13%
1,305,140
– –
VKTX icon
62
Viking Therapeutics
VKTX
$3.75B
$1.87M 0.12%
+22,818
New +$1.02M
TERN
63
DELISTED
Terns Pharmaceuticals
TERN
$1.86M 0.12%
+283,034
New +$1.85M
JBIO
64
Jade Biosciences
JBIO
$1.33B
$1.6M 0.11%
1,547
+112
+8% +$85.5K
CVAC
65
DELISTED
CureVac
CVAC
$1.56M 0.1%
515,691
+18,779
+4% +$65.9K
RGEN icon
66
Repligen
RGEN
$9.95B
$1.51M 0.1%
8,237
-1,747
-17% -$333K
MCRB icon
67
Seres Therapeutics
MCRB
$51.3M
$1.08M 0.07%
69,447
-18,230
-21% -$393K
AFMD
68
DELISTED
Affimed
AFMD
$882K 0.06%
166,460
-1,208
-0.7% -$6.88K
VINC
69
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$403K 0.03%
+3,979
New +$251K
ACIU icon
70
AC Immune
ACIU
$263M
$369K 0.02%
124,589
– –
A icon
71
Agilent Technologies
A
$43.4B
– –
-37,854
Closed -$5.26M
BHVN icon
72
Biohaven
BHVN
$2.33B
– –
-66,898
Closed -$2.86M
ILMN icon
73
Illumina
ILMN
$32.6B
– –
-89,039
Closed -$12.1M
IMGN
74
DELISTED
Immunogen Inc
IMGN
– –
-748,950
Closed -$22.2M
1 2
3

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q1 2024 Portfolio in Review

As of Q1 2024, Eversept Partners held 74 positions worth $1.5B, up 32% from $1.14B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Eversept Partners deployed $95.2M of net new capital in Q1 2024, opening 17 new positions and adding to 21 existing holdings. Its largest new stake was Pfizer: 1,102,042 shares worth $30.6M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 90% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Natera, an estimated $35.6M trimmed.

  • Eversept Partners's largest Q1 2024 buy was Pfizer: 1,102,042 shares worth $30.6M.
  • Eversept Partners added most to GSK in Q1 2024, an estimated $33M increase.
  • Eversept Partners's biggest Q1 2024 reduction was Natera, cutting an estimated $35.6M.
  • Eversept Partners fully exited Immunogen Inc in Q1 2024, selling an estimated $22.2M.
  • Eversept Partners's ten largest holdings make up 63% of its $1.5B portfolio in Q1 2024.
  • Eversept Partners opened 17 new positions and closed 4 in Q1 2024.
  • Eversept Partners's portfolio value rose 32% quarter-over-quarter to $1.5B.

Based on Eversept Partners's 13F filing for Q1 2024, filed 15 May 2024.